Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?

Metabolically associated fatty liver disease (MAFLD) is a liver manifestation of metabolic syndrome potentially related to unfavorable hepatic and extrahepatic outcomes and progression to cirrhosis. Up to date, there are no approved pharmacotherapies for the treatment of MAFLD, so management focused...

Descripción completa

Detalles Bibliográficos
Autores principales: Cigrovski Berkovic, Maja, Rezic, Tanja, Bilic-Curcic, Ines, Mrzljak, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Opinion Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297405/
https://www.ncbi.nlm.nih.gov/pubmed/36051145
http://dx.doi.org/10.12998/wjcc.v10.i20.6759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297405/
https://www.ncbi.nlm.nih.gov/pubmed/36051145
http://dx.doi.org/10.12998/wjcc.v10.i20.6759

Ejemplares similares